Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL)

14588 Background: Vorinostat, a histone deacetylase inhibitor, was approved in 2006 by the FDA for the treatment of the cutaneous manifestations of CTCL in patients with progressive, persistent, or...